Neuropilin-1 expression in cancer and development

Journal of Pathology

Volumn 226, Issue 1, 2012, Pages 50-60

  Jubb, Adrian M ^a   Strickland, Laura A ^a   Liu, Scot D ^a   Mak, Judy ^a   Schmidt, Maike ^a   Koeppen, Hartmut ^a  

^a GENENTECH INC   (United States)

Author keywords

cancer; development; immunofluorescence; immunohistochemistry; in situ hybridization; neuropilin 1; VEGF

Indexed keywords

FORMALDEHYDE; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7130; NEUROPILIN 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; EMBRYO; ENDOCARDIUM; ENDOTHELIUM; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; NERVOUS SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; ORGANOGENESIS; PERICYTE; PERINATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRACHEA; TUMOR XENOGRAFT; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; DISEASE PROGRESSION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROPILIN-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 82755184122     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2989     Document Type: Article

References (36)

1. Staton CA, Kumar I, Reed MW, et al., Neuropilins in physiological and pathological angiogenesis. J Pathol 2007; 212: 237-248. (Pubitemid 47010058)
2. He Z, Tessier-Lavigne M,. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 1997; 90: 739-751. (Pubitemid 27357965)
3. Kolodkin AL, Levengood DV, Rowe EG, et al., Neuropilin is a semaphorin III receptor. Cell 1997; 90: 753-762. (Pubitemid 27357966)
4. Takashima S, Kitakaze M, Asakura M, et al., Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A 2002; 99: 3657-3662. (Pubitemid 34252162)
5. Kitsukawa T, Shimono A, Kawakami A, et al., Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 1995; 121: 4309-4318. (Pubitemid 26007578)
6. Herzog Y, Kalcheim C, Kahane N, et al., Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech Dev 2001; 109: 115-119. (Pubitemid 33035924)
7. Yuan L, Moyon D, Pardanaud L, et al., Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002; 129: 4797-4806. (Pubitemid 35282411)
8. Appleton BA, Wu P, Maloney J, et al., Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J 2007; 26: 4902-4912. (Pubitemid 350191304)
9. Soker S, Miao HQ, Nomi M, et al., VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 2002; 85: 357-368. (Pubitemid 34274903)
10. Soker S, Takashima S, Miao HQ, et al., Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745. (Pubitemid 28155313)
11. Keyt BA, Nguyen HV, Berleau LT, et al., Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996; 271: 5638-5646.
12. Pan Q, Chanthery Y, Liang WC, et al., Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007; 11: 53-67. (Pubitemid 46054517)
13. Pan Q, Chathery Y, Wu Y, et al., Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem 2007; 282: 24049-24056. (Pubitemid 47328044)
14. Cai H, Reed RR,. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. J Neurosci 1999; 19: 6519-6527. (Pubitemid 29347451)
15. Bachelder RE, Crago A, Chung J, et al., Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001; 61: 5736-5740. (Pubitemid 32769088)
16. Castro-Rivera E, Ran S, Thorpe P, et al., Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci U S A 2004; 101: 11432-11437. (Pubitemid 39038364)
17. Cao Y, Wang L, Nandy D, et al., Neuropilin-1 upholds dedifferentiation and propagation phenotypes of renal cell carcinoma cells by activating Akt and sonic hedgehog axes. Cancer Res 2008; 68: 8667-8672.
18. Hong TM, Chen YL, Wu YY, et al., Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res 2007; 13: 4759-4768.
19. Fukahi K, Fukasawa M, Neufeld G, et al., Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin Cancer Res 2004; 10: 581-590. (Pubitemid 38173997)
20. Hansel DE, Wilentz RE, Yeo CJ, et al., Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am J Surg Pathol 2004; 28: 347-356. (Pubitemid 38269568)
21. Korsisaari N, Kasman IM, Forrest WF, et al., Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc + /min mice. Proc Natl Acad Sci U S A 2007; 104: 10625-10630. (Pubitemid 47185715)
22. Finkle D, Quan ZR, Asghari V, et al., HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004; 10: 2499-2511. (Pubitemid 38445712)
23. Singh M, Lima A, Molina R, et al., Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nature Biotechnol 2010; 28: 585-593.
24. Jubb AM, Pham TQ, Frantz GD, et al., Quantitative in situ hybridization of tissue microarrays. Methods Mol Biol 2006; 326: 255-264.
25. Liang WC, Wu X, Peale FV, et al., Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281: 951-961.
26. Caunt M, Mak J, Liang WC, et al., Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008; 13: 331-342. (Pubitemid 351446192)
27. Viera AJ, Garrett JM,. Understanding interobserver agreement: the kappa statistic. Fam Med 2005; 37: 360-363. (Pubitemid 40656185)
28. Gagnon ML, Bielenberg DR, Gechtman Z, et al., Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc Natl Acad Sci U S A 2000; 97: 2573-2578. (Pubitemid 30159212)
29. Ghosh S, Sullivan CA, Zerkowski MP, et al., High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum Pathol 2008; 39: 1835-1843.
30. Lantuejoul S, Constantin B, Drabkin H, et al., Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. J Pathol 2003; 200: 336-347. (Pubitemid 36827308)
31. Parikh AA, Fan F, Liu WB, et al., Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 2004; 164: 2139-2151. (Pubitemid 38669361)
32. Stephenson JM, Banerjee S, Saxena NK, et al., Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer. Int J Cancer 2002; 101: 409-414.
33. Yacoub M, Coulon A, Celhay O, et al., Differential expression of the semaphorin 3A pathway in prostatic cancer. Histopathology 2009; 55: 392-398.
34. Williams CK, Li JL, Murga M, et al., Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006; 107: 931-939. (Pubitemid 43156289)
35. Hellstrom M, Phng LK, Hofmann JJ, et al., Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007; 445: 776-780. (Pubitemid 46279716)
36. Lu Y, Xiang H, Liu P, et al., Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration. MAbs 2009; 1: 364-369.